Ticker Launch
Sign inTry it free

SPAC · Merger completed

FS Development Corp.

Business combination with Gemini Therapeutics, Inc.

FS Development Corp. is a blank-check company (SPAC) that completed its initial public offering on Aug 13, 2020, listing on Nasdaq Capital Market. It completed its business combination with Gemini Therapeutics, Inc. on Feb 5, 2021; the combined company is Gemini Therapeutics, Inc. (GMTX). Foresite Capital led the IPO. White & Case advised the SPAC and Skadden, Arps advised the underwriters on the IPO.

Gemini Therapeutics is a clinical-stage precision medicine company developing treatments for age-related macular degeneration matched to specific genetic mutations. Its lead candidate, GEM103, is a recombinant complement factor H protein in a Phase 2a trial in dry AMD patients with a complement factor H mutation.

Status
Merger completed
IPO date
Aug 13, 2020
IPO exchange
Nasdaq Capital Market
Target
Gemini Therapeutics, Inc. (Old Gemini)
Announced
Oct 15, 2020
Closed
Feb 5, 2021
Combined company
Gemini Therapeutics, Inc. (GMTX)
IPO underwriters
Foresite Capital
SPAC counsel (IPO)
White & Case
Underwriters' counsel (IPO)
Skadden, Arps

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2021